Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq.

Mody RM, Lakhal-Naouar I, Sherwood JE, Koles NL, Shaw D, Bigley DP, Co EA, Copeland NK, Jagodzinski LL, Mukbel RM, Smiley RA, Duncan RC, Kamhawi S, Jeronimo SMB, DeFraites RF, Aronson NE.

Clin Infect Dis. 2019 May 30;68(12):2036-2044. doi: 10.1093/cid/ciy811.

PMID:
30239631
2.

Leishmania infantum-chagasi activates SHP-1 and reduces NFAT5/TonEBP activity in the mouse kidney inner medulla.

Zhou X, Wang H, Koles NL, Zhang A, Aronson NE.

Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F516-24. doi: 10.1152/ajprenal.00006.2014. Epub 2014 Jul 2. Erratum in: Am J Physiol Renal Physiol. 2014 Oct 15;307(8):F990.

3.

Expression of a thyroglobulin (Tg) variant in mouse kidney glomerulus.

Wu H, Suzuki S, Sellitti DF, Doi SQ, Tanigawa K, Aizawa S, Akama T, Kawashima A, Mishima M, Ishii N, Yoshida A, Hisatome I, Koles NL, Katoh R, Suzuki K.

Biochem Biophys Res Commun. 2009 Nov 13;389(2):269-73. doi: 10.1016/j.bbrc.2009.08.129. Epub 2009 Aug 28.

PMID:
19716808
4.

Dose-dependent effects of recombinant human interleukin-11 on the systemic hemodynamic function and urination.

Honma K, Koles NL, Alam HB, Keith JC Jr, Pollack M.

Kurume Med J. 2007;54(3-4):73-6.

5.
6.

Dual effects of LPS antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions.

Pollack M, Ohl CA, Golenbock DT, Di Padova F, Wahl LM, Koles NL, Guelde G, Monks BG.

J Immunol. 1997 Oct 1;159(7):3519-30.

PMID:
9317151
7.

Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.

Preston MJ, Ger├žeker AA, Koles NL, Pollack M, Pier GB.

Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1418-25.

PMID:
9191605
8.
9.

Lipopolysaccharide (LPS)-specific monoclonal antibodies regulate LPS uptake and LPS-induced tumor necrosis factor-alpha responses by human monocytes.

Pollack M, Espinoza AM, Guelde G, Koles NL, Wahl LM, Ohl CA.

J Infect Dis. 1995 Sep;172(3):794-804.

PMID:
7658073
11.

Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry.

Evans ME, Pollack M, Koles NL, Hardegen NJ, Panopoulos D.

J Infect Dis. 1992 Oct;166(4):803-11.

PMID:
1527415
13.

In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides.

Pollack M, Tao M, Akiyama M, Pier GB, Koles NL.

Antibiot Chemother (1971). 1991;44:163-71. No abstract available.

PMID:
1801635
14.

Fluorescence-activated cell sorter analysis of binding by lipopolysaccharide-specific monoclonal antibodies to gram-negative bacteria.

Evans ME, Pollack M, Hardegen NJ, Koles NL, Guelde G, Chia JK.

J Infect Dis. 1990 Jul;162(1):148-55.

PMID:
2355191
15.

Lipopolysaccharide (LPS)-reactive monoclonal antibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse-derived macrophages.

Chia JK, Pollack M, Guelde G, Koles NL, Miller M, Evans ME.

J Infect Dis. 1989 May;159(5):872-80.

PMID:
2651532
16.

Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide.

Pollack M, Chia JK, Koles NL, Miller M, Guelde G.

J Infect Dis. 1989 Feb;159(2):168-88.

PMID:
2915151
17.

Monoclonal antibodies that recognize epitopes in the core and lipid A region of lipopolysaccharides.

Pollack M, Chia JK, Koles NL, Miller M, Guelde G.

Prog Clin Biol Res. 1988;272:327-38. No abstract available.

PMID:
2455917

Supplemental Content

Loading ...
Support Center